Real-world Treatment Outcomes in Black, Hispanic, Asian, and White People with Multiple Sclerosis Treated with Fumarates (P4-6.005).

Objective: To assess the effectiveness of fumarates (FUM) in Black, Hispanic, Asian, and White people with multiple sclerosis (pwMS).

Background: Racial/ethnic minority patient populations are generally underrepresented in clinical trials. Dimethyl fumarate (DMF) and diroximel fumarate (DRF) are disease-modifying therapies for relapsing MS.

Outcomes in a Modern Cohort of Treated Patients with Multiple Sclerosis from Diagnosis Up to 15 Years.

Background: Before disease-modifying therapies (DMTs) were available, the natural history of multiple sclerosis (MS) regarding attainment of accepted disability milestones was reported with fairly wide variance comparing outcomes across studies. The influence of DMTs on these outcomes is unknown. This study aimed to calculate attainment of disability milestones during the first 15 years after onset of DMT-treated relapsing forms of MS (RMS).

Multiple sclerosis relapses contribute to long-term disability.

Background: Treatments affect both relapse-related disability and short-term disability change, but measurements of their impact on long-term outcomes remain a challenge.

Objective: To ascertain the contribution of relapse-associated disability to overall disability in relapse-onset multiple sclerosis (RMS) using long-term data collected in our clinic.

Materials And Methods: Retrospective study of a cohort of newly diagnosed patients with RMS, (n = 176) was undertaken, measuring all confirmed changes in disability up to 15 years after onset.

A review and update on the diagnosis and treatment of neuropsychiatric Wilson disease.

: This paper reviews the presenting signs and symptoms of Wilson's disease, with an emphasis on the recognition and treatment of neuropsychiatric symptoms. : A literature search was conducted using PubMed.gov utilizing the following keywords: Wilson disease, neuropsychiatric, psychiatric symptoms, treatment, antipsychotics, mood stabilizer, psychotherapy, antidepressant, ATP7B.

Specific clinical phenotypes in relapsing multiple sclerosis: The impact of relapses on long-term outcomes.

Objective: The impact of relapses on the disease course of relapsing MS remains to be determined. This study aims to identify and characterize clinical phenotypes of relapse onset MS in a longitudinally studied cohort.

Methods: We recorded the clinical course of MS during the first decade of disease, using five-year epochs.

Whole-genome profiling in liposarcomas reveals genetic alterations common to specific telomere maintenance mechanisms.

Telomere attrition ultimately leads to the activation of protective cellular responses, such as apoptosis or senescence. Impairment of such mechanisms can allow continued proliferation despite the presence of dysfunctional telomeres. Under such conditions, high levels of genome instability are often engendered.